BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Takeda Pharmaceutical Co. Ltd. (TKPYY) Looks to Join Top Global Vaccine Players


11/9/2012 9:05:22 AM

The ambitions of Takeda Pharmaceutical Co. 4502.TO -0.81% go well beyond its $14 billion cross-border acquisition of Nycomed: Japan's biggest drug maker now wants to rub shoulders with the likes of GlaxoSmithKline GSK.LN -0.11% PLC and Sanofi SA SAN.FR +1.48% as a global leader in the lucrative market for vaccines. Fueled by demand from emerging countries like China and India, the vaccines business is set to grow by more than half to at least $30 billion over the next five years, market watchers say. This year's new global push by Takeda, still ranked only 12th by sales among drug makers world-wide, comes as industry players reassess the appeal of vaccines amid a flood of generic products that has cut into the profits of blockbuster treatments. Though costly and time-consuming to develop, vaccines are nearly impossible to copy in generic form. Analysts believe it is too early to make a call on the scale of Takeda's vaccines potential from its current base of just under $300 million in annual revenue. But the firm has surprised even skeptics with the speed with which it has been planting its seeds, luring talent from overseas and hunting aggressively for technologies that will lift it into the top ranks.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->